Please assess the completion status of the following clinical trial:

Trial Title: E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Subjects with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).~2. Locally advanced and/or metastatic non-small cell lung cancer (NSCLC) (Stage IIIB/IV).~3. Subjects with at least one measurable tumor lesion by Response Evaluation Criteria In Solid Tumors (RECIST).~4. Subjects with Performance Status (PS) 0-1.~5. Subjects with adequate organ function.~Exclusion criteria:~1. Subjects who have ever received the following therapy for non-small cell lung cancer (NSCLC):~   1. Chemotherapy~  2. Biological or immunotherapies~  3. Surgery for primary focus~  4. The radiation therapy for primary focus~2. Subjects with the severe complications or disease history.~3. Subjects with brain metastasis accompanying clinical symptoms or requiring treatment.~4. Subjects with simultaneous or metachronous cancers.~5. Subjects who cannot take oral medication.~6. Subjects who are using drugs that strongly inhibit or induce cytochrome P450 (CYP) 3A4.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- E7080 (Dose Escalation Cohort) (Type: EXPERIMENTAL): This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
- E7080 (Expansion Cohort) (Type: EXPERIMENTAL): Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).